Moderna Competitors and Similar CompaniesClear all
Moderna's competitors and similar companies include Alnylam, Celyad and Sarepta Therapeutics.
 Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |
Founding Date | Founding Date 2010 | Founding Date 2002 | Founding Date 2007 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | ||
Employees | Employees 5,60044% increase | Employees 1,32324% increase | Employees 17 | Employees 1,31413% increase |
Valuation ($) | Valuation ($) 21.2 b | Valuation ($) 36.5 b | Valuation ($) 11.8 m | Valuation ($) 12.4 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $3.2b (FY, 2024) | Revenue (est.) $2.2b (FY, 2024) | Revenue (est.) €186k (FY, 2024) | Revenue (est.) $1.9b (FY, 2024) |
Cost of goods | Cost of goods $1.5b (FY, 2024) | Cost of goods $306.5m (FY, 2024) | Cost of goods €12k (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit $1.8b (FY, 2024) | Gross profit $1.9b (FY, 2024) | Gross profit €602k (FY, 2024) | Gross profit N/A |
Net income | Net income ($3.6b) (FY, 2024) | Net income ($278.2m) (FY, 2024) | Net income (€5.8m) (FY, 2024) | Net income $235.2m (FY, 2024) |
Funding | ||||
Total funding raised | Total funding raised $ 1.8b | Total funding raised $ 1.5b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyCelyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View company